Drug Profile
GPR142 agonist - Eli Lilly and Company
Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antihypercalcaemics; Benzamides; Imidazoles; Small molecules
- Mechanism of Action G protein-coupled receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA
- 09 Mar 2018 Eli Lilly has patents pending for GPR142 agonists in Japan, Europe, South Korea, Canada, Australia and Mexico
- 09 Mar 2018 Eli Lilly has patent protection for GPR142 agonists in USA